GlassScriptPhysician profile
Rajwinder Kaur
NPI 1245635887
$2,102.15
in general payments reported to CMS, 2019-2025
18 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $341 · 2022: $462 · 2023: $272 · 2024: $592 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $941.73 | 2021-2024 | |
| Axsome Therapeutics, INC. | $247.17 | 2023-2024 | Auvelity |
| Opko Pharmaceuticals, LLC | $153.13 | 2024-2025 | Rayaldee |
| Astellas Pharma US INC | $140.35 | 2024-2025 | Ambisome, Cresemba |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.64 | 2022 | |
| Lilly USA, LLC | $79.92 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $69.11 | 2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $61.80 | 2024-2025 | Verquvo |
| Janssen Biotech, INC. | $57.91 | 2022 | |
| Pfizer INC. | $45.52 | 2025 | |
| Becton, Dickinson and Company | $33.59 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $28.52 | 2024 | Farxiga |
| Ani Pharmaceuticals, INC. | $24.22 | 2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $23.64 | 2025 | |
| Almatica Pharma LLC | $22.83 | 2025 | Loreev Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $20.96 | 2025 | Attruby |
| Exact Sciences Corporation | $20.52 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $16.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajwinder Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.